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The alternative or noncanonical nuclear factor kappa B (NF-κB)
pathway regulates the osteoclast (OC) response to receptor acti-
vator of nuclear factor kappa B ligand (RANKL) and thus bone
metabolism. Although several lines of evidence support the emerg-
ing concept that nucleotide-binding leucine-rich repeat and pyrin
domain-containing receptor 12 (NLRP12) impedes alternative NF-κB
activation in innate immune cells, a functional role for NLRP12 out-
side an inflammatory disease model has yet to be reported. Our
study demonstrates that NLRP12 has a protective role in bone via
suppression of alternative NF-κB–induced osteoclastogenesis and is
down-modulated in response to osteoclastogenic stimuli. Here, we
show that retroviral overexpression of NLRP12 suppressed RelB
nuclear translocation and OC formation. Conversely, genetic abla-
tion of NLRP12 promoted NIK stabilization, RelB nuclear transloca-
tion, and increased osteoclastogenesis in vitro. Using radiation
chimeras, we demonstrated these in vitro observations dovetail
with our in vivo findings that NLRP12 deficiency leads to enhanced
OC numbers accompanied by a significant decline in bone mass
under physiological conditions. Consistent with the basal bone
phenotype, we also observed an enhanced osteolytic response
following RANKL injection over the calvaria of NLRP12-deficient
chimeric mice compared with wild-type control mice. Thus, modu-
lation of NLRP12 levels controls alternative NF-κB signaling in OC
precursors, altering bone homeostasis and osteolytic responses.
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The unique capacity of osteoclasts (OCs) to resorb bone, inboth physiological and pathological contexts, highlights the
importance for understanding the molecular mechanisms con-
trolling their development and activity (1). OCs originate from
myeloid/macrophage lineage cells in the bone marrow. Macro-
phage colony-stimulating factor (M-CSF) is a hematopoietic
growth factor that not only promotes proliferation and survival
of myeloid progenitors but also induces expression of receptor
activator of NF-κB (RANK), the receptor for RANKL. RANKL,
a tumor necrosis factor (TNF) superfamily member, works in
concert with M-CSF to instruct myeloid precursor cells to undergo
differentiation into OCs and orchestrates the activation of several
essential downstream signaling pathways, including both classical
and alternative nuclear factor-κB (NF-κB).
In addition to its well-characterized role in host defense and
modulating inflammatory responses in immune cells, NF-κB has a
critical utility in controlling skeletal mass via its regulatory role in
OC development. In the classical pathway, RANK ligation triggers
the degradation of NF-κB–associated IκBs. Consequently, the
pathway is activated by lifting this cytoplasmic restraint to allow
the nuclear translocation of several NF-κB complexes, mainly the
p50/p65 (RelA) heterodimer, to induce transcription of target
genes. Using a combination of genetic and biochemical approaches,
we previously demonstrated that the NF-κB subunit p65 blocks the
RANKL-associated cell death pathway during OC differentiation
(2). In this respect, p65 behaves as a prosurvival factor that supports
OC development indirectly by preventing JNK-mediated RANKL-
induced apoptosis. The alternative NF-κB pathway regulates OC
differentiation independently of controlling prosurvival pathways
and uses a different repertoire of adaptors and kinases to transduce
signal. Intracellular accumulation and stability of NF-κB–inducing
kinase (NIK) is an essential prerequisite for instigating alternative
NF-κB signaling. In this regard, NIK behaves as a regulatory switch
because its RANKL-induced accumulation leads to activation of
inhibitor of κB kinase alpha (IKKα). This kinase targets p100,
leading to its processing to p52, and promotes the subsequent
translocation of the p52/RelB NF-κB heterodimer into the nucleus
to drive gene expression. Genetic ablation of NIK or RelB severely
impairs OC formation in vitro (3, 4). Intriguingly, both NIK and
RelB-deficient mice exhibit relatively normal OC function in vivo
under physiological conditions; however, they are very resistant to
multiple forms of pathological bone loss (3, 4). Moreover, the
differentiation defect in Nik−/− or RelB−/−OC precursors is rescued
by virally reconstituting the expression of RelB, the key sig-
naling component downstream of NIK, thus demonstrating
that both NIK and RelB are critical components of alternative
NF-κB–mediated osteoclastogenesis.
In the absence of receptor ligation, de novo NIK does not
detectably accumulate and undergoes constitutive degradation as
a consequence of its direct association with TNFR-associated
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factor 3 (TRAF3), an intrinsic negative regulatory component
of the E3 ligase complex (TRAF2:TRAF3:cIAP1/2) (5–8). Re-
cruitment by TRAF3 brings NIK into close molecular proximity
with other complex members, TRAF2 and cellular inhibitor of
apoptosis 1/2 (cIAP1/2), the latter of which ubiquitylates NIK,
leading to its proteasomal degradation. Hence, recruitment of
NIK by the E3 ligase regulatory complex is a molecular restraint
that renders the alternative NF-κB pathway inactive under basal
conditions.
NLRP12, a recently identified nucleotide-binding leucine-
rich repeat and pyrin domain-containing receptor (NLR),
possesses a characteristic NLR tripartite domain architecture
that facilitates the assembly of multimeric complexes encom-
passing a wide spectrum of recruited adaptors and kinases. NLRs
are intracellular pattern-recognition receptors that function as
signaling platforms of the innate immune system in response to
internal danger signals such as microbial challenge and envi-
ronmental stressors. Historically, most NLRs have been ascribed
a proinflammatory role, with most possessing inflammasome-
activating potential. However, NLRP12 has been assigned to
an emerging class of inhibitory or checkpoint NLRs (9–11),
although it can exhibit inflammasome function with specific
stimuli (12, 13). NLRP12 is predominately expressed in immune
cells, specifically cells of the myeloid/monocytic lineage, in-
cluding macrophages, granulocytes, and immature dendritic cells
(14–17). Intriguingly, NLRP12 expression is induced by nitric
oxide but transcriptionally down-regulated in response to path-
ogens, their products, and proinflammatory molecules, thus en-
gendering the notion that NLRP12 functions to restrain inputs
that promote innate immune responses. Indeed, NLRP12 has
been reported to negate the function of several important
effector molecules downstream of TNFR and toll-like receptor
(TLR) signaling such as NIK and IRAK-1 in human monocytes
(11, 14, 16, 18). Of note, all of the presently known inhibitory
NLRs function to attenuate classical NF-κB signal transduction,
but NLRP12 has uniquely been demonstrated to also impede
alternative NF-κB activation (10, 14). Mechanistically, NLRP12
blocks the hyperphosphorylation of IRAK-1, ultimately limiting
downstream activation of the classical NF-κB pathway, and
NLRP12 deficiency potentiates phosphorylation of p105 and
nuclear trafficking of p65 in response to TLR ligation (15, 19).
NLRP12 was also shown to antagonize alternative NF-κB in
monocytes by directly associating with TRAF3 and NIK, thus
limiting basal activation of the pathway by preventing the deg-
radation of TRAF3 and instigating the proteasomal degradation
of NIK (11, 14, 16, 18, 20, 21).
Here we show that NLRP12 is transcriptionally down-regulated
in response to osteoclastogenic cytokines M-CSF and RANKL
and functions as a critical checkpoint protein of alternative
NF-κB–mediated osteoclastogenesis. We also provide genetic
evidence that NLRP12 has a fundamental physiological and
pathophysiological role in bone turnover as NLRP12 deficiency
promotes OC formation and decreases bone mass in vivo. To-
gether, these data clearly demonstrate a role for NLRP12 outside
the context of controlling innate immunity.
Results
NLRP12 Deficiency Potentiates Osteoclast Formation. Because
NLRP12 regulates NF-κB pathways in myeloid lineage cells, we
tested whether NLRP12 deficiency modulates OC formation, a
process dependent on NF-κB. First, wild-type (Wt) and Nlrp12−/−
unfractionated whole bone-marrow cells were cultured in vitro
Fig. 1. NLRP12 deficiency augments OC formation and expression of OC-specific genes in vitro.Wt and Nlrp12−/− unfractionated whole bone marrow (WBM)
(A) or BMM (B) cells were cultured under osteoclastogenic conditions for 4–5 d. Differentiation was assessed by quantitating the number of multinucleated
(more than three nuclei per cell) TRAP-positive cells. (C) BMMs induced to differentiate into OCs in the presence of M-CSF and RANKL (30 ng/mL) were
analyzed by quantitative RT-PCR for relative expression of cathepsinK, calcitonin receptor, and DC-Stamp, normalized to cyclophilin. Data show mean ± SD of
three independent experiments. *P < 0.05, **P < 0.01.
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with M-CSF and RANKL for 6 d to generate OCs. As shown in
Fig. 1A, NLRP12 deficiency increases the formation of multi-
nuclear tartrate-resistant acid phosphatase (TRAP)-positive cells
(three or more nuclei) relative to Wt over a range of RANKL
doses. To determine whether this result could be due to an ex-
pansion in the number of OC precursors, we performed flow
cytometry on unfractionated whole bone marrow and found the
proportion of cells in CD11b/GR1 fractions to be unchanged, as
was the level of CD117 in these fractions (Fig. S1). We then
differentiated OCs from M-CSF–expanded bone marrow mac-
rophages (BMMs) and observed a similar enhancement of
OC formation in NLRP12-deficient cultures compared with Wt
controls (Fig. 1B). Reflecting a greater number of mature OCs
in Nlrp12−/− cultures, transcript levels of OC differentiation
markers cathepsin K, DC-Stamp, and calcitonin receptor were
all significantly elevated in the absence of the NLRP12 at a low
dose of RANKL (Fig. 1C). However, proliferation and RANK
expression in response to M-CSF and RANKL were comparable
between Wt and NLRP12-deficient BMMs (Fig. S2). Taken to-
gether, these results suggest that NLRP12 provides a checkpoint
for osteoclastogenesis by reducing sensitivity of OC precursors to
RANKL rather than changing the number of precursors avail-
able for differentiation.
NLRP12 Is Down-Regulated by M-CSF and RANKL. Because NLRP12
deficiency promoted OC differentiation from both the early
precursors present in whole bone marrow as well as expanded
BMMs, we expected to find NLRP12 down-regulation in re-
sponse to RANKL. To examine Nlrp12 expression in response to
osteoclastogenic stimuli, we exposed unfractionated whole bone-
marrow cells to M-CSF in vitro for 48–72 h, with or without
RANKL. As expected, RANKL treatment decreased Nlrp12
transcript levels compared with M-CSF alone, as determined by
quantitative RT-PCR (Fig. 2A). Surprisingly, we also observed a
dramatic (10-fold) decrease in Nlrp12 expression between 48 and
72 h in M-CSF alone. Next, we performed a similar experiment,
this time starting with BMMs that had been expanded from
whole marrow for 4 d in M-CSF (control) and treated with
M-CSF, with or without RANKL, for an additional 24–48 h.
Again, RANKL decreased Nlrp12 levels compared with M-CSF
alone at 24 h, but by 48 h, levels were very low and not different
between conditions (Fig. 2B). Furthermore, Nlrp12 levels remain
low in mature OCs (Fig. S3). These results demonstrate that
Nlrp12 transcription is down-regulated during M-CSF–driven dif-
ferentiation of murine myeloid progenitors and is further reduced
by costimulation with RANKL. Given that Nlrp12−/− cultures
showed enhanced osteoclastogenesis from both early and late pre-
cursor populations (corresponding to those examined for Nlrp12
expression here), it appears that NLRP12 maintains its checkpoint
function over a wide range of expression levels.
NLRP12 Suppresses Alternative NF-κB Activation in Osteoclast Precursors.
Because NF-κB drives OC differentiation in response to RANKL
and several reports demonstrate that NLRP12 attenuates NF-κB
activation to control inflammatory responses in myeloid cells, we
sought to investigate whether the absence of NLRP12 in OC pre-
cursors would lead to the hyperactivation of NF-κB. To clarify
whether NLRP12 impacts the classical NF-κB pathway leading to
p65 activation, we examined the levels of p65 protein in the nuclear
and cytoplasmic fractions of Wt and NLRP12-deficient BMMs in
response to RANKL. As shown in Fig. 3A, the nuclear translocation
of p65 was comparable between Wt and NLRP12-deficient BMMs
Fig. 2. Nlrp12 expression is suppressed during osteoclastogenesis in vitro.
(A) WBM cells (Ctrl, 0 h) were cultured with M-CSF alone or M-CSF and
RANKL (30 ng/mL) for 48 and 72 h, then analyzed by quantitative RT-PCR for
Nlrp12 expression, normalized to cyclophilin. (B) BMM cells (Ctrl, 0 h), gen-
erated by culturing in M-CSF for 4 d, were further cultured in M-CSF with or
without RANKL (30 ng/mL) for 24 and 48 h, then analyzed as in A. Data show
mean ± SD of three independent experiments. ***P < 0.001.
Fig. 3. NLRP12 deficiency enhances alternative NF-κB activation. Wt and
Nlrp12−/− BMMs were stimulated with RANKL (30 ng/mL) for the times in-
dicated. Extracts from the nuclear (Top NE) and cytoplasmic (Bottom CE)
fractions were analyzed by immunoblot for p65 (A) or RelB (B). (C) NIK was
assessed by immunoblot analysis from whole cell lysates of Wt and NLRP12-
deficient BMMs stimulated with RANKL (30 ng/mL) for the times indicated.
Control in C (Ctrl) isWt BMMs treated with MG-132 (10 μM) for 4 hr. Data are
representative of three independent experiments.





















for all time points observed, suggesting that the suppressive effect of
NLRP12 on OC formation is likely not mediated by p65 inhibition.
To address whether loss of NLRP12 affects the alternative NF-
κB pathway in OC precursors, we stimulated Wt and Nlrp12−/−
BMMs with RANKL and monitored levels of RelB, a key alter-
native pathway subunit, in the nuclear and cytoplasmic fractions
(Fig. 3B). NLRP12 deficiency significantly enhanced the trans-
location of RelB into the nuclear compartment, including in
unstimulated BMMs and with 24–72 h of RANKL stimulation,
compared with Wt controls. This activation of alternative NF-κB
occurred upstream at the level of NIK stabilization, as we ob-
served increased levels of NIK protein in BMMs, with or without
RANKL treatment in the absence of NLRP12 (Fig. 3C).
Because Nlrp12 expression is rapidly down-regulated by
RANKL, we asked if overexpression of this molecule could in-
hibit OC differentiation. To this end, we cloned a FLAG-tagged
Nlrp12 cDNA into the pMX retroviral vector and transduced
Wt BMMs with this retrovirus. Following blasticidin selection,
transduced cells were cultured in osteoclastogenic conditions. OC
numbers were significantly reduced in cultures overexpressing
NLRP12, compared with those transduced with empty vector (Fig.
4A). Supporting a role for NLRP12 in inhibiting alternative NF-
κB, RANKL-induced RelB nuclear translocation was significantly
reduced by NLRP12 overexpression (Fig. 4B). These data indicate
that NLRP12 alters the cellular response of myeloid precursors to
osteoclast-inducing stimuli by limiting activation of the alternative
NF-κB pathway.
NLRP12 Limits Osteoclastogenesis and Bone Resorption in Vivo.Next, we
sought to characterize the physiological role of NLRP12 on OC
development and bone resorption in vivo. Although NLRP12 ex-
pression is primarily found in cells of myeloid lineage, we generated
radiation chimeras to exclude any modulatory effects of NLRP12 in
osteoblasts. Eight weeks after bone marrow transplantation into
wild-type recipients, micro-CT analysis of tibiae revealed that the
trabecular bone volume fraction (BV/TV) was significantly reduced
in recipients of NLRP12-deficient marrow compared with Wt con-
trols (Fig. 5A). Likewise, NLRP12 deficiency coincided with a
marked decrease in bone mineral density accompanied by signifi-
cant trabecular thinning (Fig. 5 B and C). In support of these
findings, histomorphometric analysis demonstrated a significant
increase in OC number and surface (Fig. 5 D–F) in radiation
chimeras bearing NLRP12-deficient bone marrow relative to Wt.
We and others have previously shown that genetic ablation of
critical components of alternative NF-κB signaling render mice
severely impaired in their ability to form OCs in vitro and re-
calcitrant to multiple forms of pathological bone loss in vivo
(3, 22–26). Therefore, we next wanted to assess the protective
potential of NLRP12 under pathological, yet noninflammatory
conditions. To address this question, we turned to a RANKL-
induced bone loss model, in which RANKL was injected daily
over the periosteum of mouse calvaria for 5 d. Echoing the basal
bone phenotype, we observed an enhanced osteolytic response of
NLRP12 chimeric mice relative to controls, as assessed by micro-
CT (Fig. 6A). Quantitation of volumetric bone mineral density
for the crown of the calvaria, relative to PBS controls, demon-
strates that NLRP12-deficient mice exhibit a 50% increase in
bone resorption in response to RANKL injection compared with
Wt controls (Fig. 6B). Collectively, the findings indicate that
NLRP12 has a protective role in bone by limiting bone re-
sorption under both homeostatic and pathological conditions,
in vivo, independent of its reported role in controlling inflammatory
responses in myeloid progenitors.
Discussion
Alternative NF-κB activation is critical for mediating OC for-
mation in vitro and for pathological osteolysis in vivo. Here, we
demonstrate that NLRP12 functions as an important checkpoint
protein that restrains alternative NF-κB–driven osteoclasto-
genesis and functions to control skeletal turnover, both basally
and under conditions of RANKL-induced osteolysis. Our study
reveals that NLRP12 has a protective role in bone and is to our
knowledge the first reported example of an NLR to suppress
osteoclastogenesis, thus expanding its biological importance be-
yond attenuating NF-κB–mediated inflammatory responses.
OC formation is dictated by external cues including M-CSF and
RANKL, which signal through their respective receptors and initiate
Fig. 4. Overexpression of NLRP12 blunts OC formation and attenuates
nuclear translocation of RelB. Wt BMMs were retrovirally infected with full-
length NLRP12 or empty vector (control), followed by M-CSF and RANKL
(30 ng/mL) stimulation. (A) OC formation was determined via enumeration
of TRAP-positive cells containing more than three nuclei. Numbers are mean ±
SD of multinuclear cells (**P < 0.01; n = 3). Data are representative of three
independent experiments. (B) Nuclear translocation of RelB was evaluated by
immunoblot analysis of nuclear fractions for the times indicated.
Fig. 5. NLRP12-deficient chimeric mice exhibit significantly lower bone
mass and enhanced osteoclast formation under basal conditions in vivo.
Wild-type mice were irradiated and reconstituted with either Wt or Nlrp12−/−
bone marrow cells. Eight weeks postreconstitution, tibias were scanned by
micro-CT and trabecular bone parameters were analyzed. (A) Bone volume per
total volume (BV/TV). (B) Bone mineral density (vBMD). (C) Trabecular thickness
(Tb.Th). (D) TRAP staining of tibial sections of mice reconstituted with Wt or
Nlrp12−/− marrow; OCs are stained red (annotated by asterisks). Histomorpho-
metric analysis was used to determine (E) osteoclast number per bone surface
(N.Oc/BS) and (F) osteoclast surface per bone surface (Oc.S/BS). All data are
mean ± SD *P < 0.05 compared with Wt; n = 10 per group.
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activation of the alternative NF-κB pathway in myeloid pro-
genitors in the bone marrow (27). We observed that NLRP12 is
transcriptionally down-regulated during myeloid differentia-
tion under conditions of prolonged M-CSF exposure, in line
with previous reports of GM-CSF differentiation-associated and
inflammatory-driven NLRP12 suppression. Strikingly, costimulation
with M-CSF and RANKL significantly augmented the repression
in unfractionated bone marrow precursors as well as BMMs,
compared with M-CSF alone. Nlrp12 expression remained ex-
tremely low in mature OCs, suggesting the NLRP12 checkpoint
function likely occurs at the level of differentiation as wild-type
osteoclasts are unlikely to contain NLRP12 at the mature, bone-
resorbing stage.
A recent study identified that B lymphocyte-induced matura-
tion protein 1 (Blimp1) binds the NLRP12 promoter, leading to
a partial inhibition of NLRP12 transcription in human mono-
cytes (28). However, it is unlikely that Blimp1 plays a significant
role in the suppression of NLRP12 in murine OC precursors, as
NLRP12 is down-regulated before RANKL-induced Blimp1 in-
duction in our culture conditions (Fig. S4). Further studies are
needed to elucidate the molecular basis of the observed M-CSF
and RANKL-mediated transcriptional repression of NLRP12.
It is intriguing that we found significant enhancement of
osteoclastogenesis in Nlrp12−/− precursors whether the differ-
entiation was initiated from whole bone marrow or expanded
BMMs, given that the latter population starts with 10-fold lower
Nlrp12 transcript levels. Although it is possible that NLRP12
protein is long-lived, and that its loss lags behind that of mRNA,
it seems unlikely that BMMs differentiated for several days re-
tain similar protein levels as early progenitors. Rather, it appears
that NLRP12 can regulate alternative NF-κB signaling over a
wide dynamic range. Unfortunately, antibody reagents are not
available at this time to address this question directly. NIK levels
also appear to be exquisitely regulated, as this protein is extremely
difficult to detect in M-CSF–expanded BMMs, and remains at the
lower limits of detection by immunoblot even after RANKL
stimulation, which should stabilize it, and when downstream
events in the alternative NF-κB pathway are readily detectable.
In fact, we found that absence of NLRP12 leads to increased
NIK stability in BMMs with or without RANKL. Congruently,
we found that nuclear accumulation of RelB was augmented in
untreated Nlrp12−/− BMMs and after exposure to RANKL. Be-
cause both NIK and RelB are critical for osteoclastogenesis
in vitro, the regulation of these alternative NF-κB proteins is the
likely mechanism by which NLRP12 limits OC differentiation.
Whereas mice lacking either NIK or RelB are resistant to
pathological bone loss in vivo, deficiency of NLRP12 has the
opposite effect, sensitizing mice to osteoclastogenic stimuli.
Using radiation chimeras, we found that loss of NLRP12 in bone
marrow cells disrupts bone homeostasis and leads to a decrease
in bone mass associated with an increase in OC numbers. Simi-
larly, we find that NLRP12 deficiency leads to an increased
susceptibility to bone loss in response to supracalvarial injection
of RANKL, a noninflammatory model of focal osteolysis that
allowed us to disengage the protective role of NLRP12 in bone
from its established role in attenuation of inflammatory re-
sponses. Because elevation of RANKL is a final common event
that occurs in most forms of pathological osteolysis, both in-
flammatory and not, and initiates critical signals through the
alternative NF-κB pathway, it is likely that NLRP12 plays an
important regulatory role in limiting most forms of bone loss.
Numerous reports have shown that NLRP12 impedes alter-
native NF-κB signaling to attenuate inflammatory responses
within the myeloid lineage (11, 15, 16, 18). NLRP12 interacts not
only with NIK, but also TRAF3, which is directly involved in
proteasome-mediated degradation of NIK, thus safeguarding
against alternative pathway activation in innate immune cells
under basal conditions. Our studies support and extend those
findings, indicating a role for NLRP12 in negatively regulating
OC development via down-regulation of the alternative NF-κB
pathway. Using human monocytes, one study demonstrated
NLRP12-mediated inhibition of classical NF-κB in response to
TLR ligation (16). However, we observed that RANKL-induced
nuclear translocation of the p65 subunit was comparable between
Wt and NLRP12-deficient BMMs, suggesting that NLRP12 does
not modulate osteoclastogenesis via the classical NF-κB pathway.
Thus, it appears that the molecular events in which NLRP12
participates are dependent on cell type and stimulus. Further-
more, NLRP12 is an adaptor molecule and its scaffolding activity
(i.e., ability to bring together other signaling molecules such as
NIK and TRAF3) could be regulated by ligands in a fashion
similar to other members of the NLR family. More work is needed
to elucidate the exact signals and interactions that determine the
effects of NLRP12.
Nlrp12 mutations in humans are linked to autoimmune he-
reditary periodic fevers that result from a loss of regulatory
control over either inflammasome formation or NF-κB activa-
tion (17, 29, 30). Musculoskeletal manifestations with associated
joint pain have been reported, but no thorough clinical evalua-
tion of bone phenotype has been conducted. By demonstrating
that NLRP12 restrains bone resorption, even in the absence of
overt inflammation, we have established a role for NLRP12
outside of controlling immune responses to inflammatory stim-
uli. Our study positions NLRP12 as a previously unidentified
member of the ever-growing list of molecules shared by bone and
the immune system that define the field of osteoimmunology,
and improved understanding of its role broadens our understanding
of the complex regulatory pathways at play.
Materials and Methods
Reagents. FBS, penicillin, and streptomycin were from Gibco-BRL. α-MEM and
MG-132 were obtained from Sigma-Aldrich. M-CSF in the form of CMG 14–
12 supernatant and GST–RANKL were prepared as previously described (4).
Antibodies for immunoblotting were from the following vendors: anti-RelB
(no. 4954), anti-p65 NF-κB (no. 3034), anti-NIK (4994S), anti-histone H3 (96C10)
(no. 3638) from Cell Signaling Technology and anti–β-actin (A2228) and anti-
FLAG (F3165) from Sigma-Aldrich.
Fig. 6. RANKL-induced osteolysis is significantly enhanced in NLRP12-
deficient chimeric mice in vivo. RANKL (1.5 mg/kg body weight) or PBS (sham
control) was injected over the calvaria of Wt or NLRP12-deficient chimeric
mice once per day for 5 d. (A) Micro-CT was used to determine the volu-
metric bone density and it was expressed as percent bone loss relative to
respective PBS controls (B). **P < 0.01 compared with Wt; n = 10 per group.





















Mice. All animal procedures were approved by Washington University and
University of North Carolina Institutional Animal Care andUse Committees, in
compliance with established federal and state policies. C57BL/6J mice (Wt)
were purchased from The Jackson Laboratory. Age and sex-matched
NLRP12-deficient bone marrow used in vitro and to generate chimeric mice
was obtained from long bones shipped overnight on ice. Nlrp12−/− mice
were generated by homologous recombination and backcrossed for nine
generations to C57BL/6J as previously described (31). For chimeric mice, re-
cipient 6-wk-old C57BL/6J mice were lethally irradiated (10 Gy total body
γ-irradiation) 8 h before injection of bone marrow cells (5 × 106) from Wt or
Nlrp12−/− donors via tail vein. Recipients were allowed to reconstitute for
6–8 wk before use.
OC Culture. To generate OCs from unfractionated bone marrow cells, bone
marrowwas harvested from the long bones of 10- to 12-wk-oldmice and cells
(5 × 104) were cultured in α-MEM plus 10% (vol/vol) FBS containing a 1:50
dilution of CMG 14–12 cell supernatant (30) (containing equivalent of 20 ng/mL
of M-CSF) and GST–RANKL at indicated doses in 96-well tissue-cultured–treated
plates with media changes every other day. To obtain OCs from enriched
BMMs, bone marrow cells were cultured in α-MEM plus 10% (vol/vol) FBS and
a 1:10 dilution of CMG 14–12 cell supernatant (containing equivalent of
100 ng/mL of M-CSF) for 4 d to expand BMMs. Nonadherent cells were re-
moved by several washes in PBS and adherent BMMs were detached with
trypsin-EDTA, plated at 8 × 103 per well in a 96-well plate and cultured as
described above. For TRAP staining, cells were fixed in 4% (vol/vol) ultrapure
formaldehyde (Polysciences) plus 0.1% Triton X-100 in PBS for 10 min at room
temperature, rinsed gently with water, and incubated with TRAP staining
solution according to manufacturer protocol (Sigma-Aldrich). Multinucleated
(more than three nuclei) TRAP-positive OCs were enumerated in triplicate
wells and counted by imaging the entire well (encompassed in a single 2×
field) using an Olympus BX41 microscope.
Quantitative Real-Time RT-PCR. Methods and primer sequences can be found
in SI Materials and Methods.
Immunoblotting and Subcellular Fractionation. Cells were lysed and processed
by standard methods detailed in SI Materials and Methods.
NLRP12 Retroviral Overexpression. Full-length human NLRP12 was PCR am-
plified with an in-frame sequence encoding a FLAG tag at the N terminus to
facilitate detection, subcloned into a pMX retroviral vector, and sequence
verified before use (16). The generated NLRP12–pMX construct was tran-
siently transfected into Plat-E packaging cells via the calcium phosphate-
precipitation method. Virus was harvested 48 h posttransfection and used to
infect BMMs for 48 h in the presence of 20 ng/mL M-CSF equivalent and 4 μg/mL
polybrene, followed by selection in blasticidin for 3 d before culture with
20 ng/mL M-CSF equivalent and GST–RANKL (30 ng/mL).
Microcomputed Tomography and Bone Histomorphometric Analysis. Calvariae
and tibias were scanned using a microcomputed tomography 40 (μCT40) or
VivaCT40 scanners (Scanco), respectively, according to guidelines for as-
sessment of bone microarchitecture in rodents (32), and data were analyzed
by a blinded observer. Further details can be found in SI Materials and
Methods. Tibias were fixed in 10% (vol/vol) neutral buffered formalin for 24 h,
processed through a series of graded alcohols, decalcified, and embedded in
paraffin for sectioning. Sections for histomorphometry were stained for TRAP.
Histomorphometric measurements were conducted by a blinded observer
according to the American Society for Bone and Mineral Research guidelines
using BIOQUANT OSTEO 2012 software (BIOQUANT Image Analysis) and
standard parameters (33).
Statistical Analysis. Data reported graphically for Nlrp12, Rank, and Blimp1
expression were evaluated by ANOVA and the Tukey–Kramer multiple
comparisons test (GraphPad InStat). For all other data, unpaired one-tailed
Student’s t tests were performed and P < 0.05 was taken as the level of
significance.
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